Accuracy of DOTATATE PET imaging in the preoperative planning of small bowel neuroendocrine tumor resection.
DOTATATE PET
neuroendocrine tumors
robotic surgery
Journal
Journal of surgical oncology
ISSN: 1096-9098
Titre abrégé: J Surg Oncol
Pays: United States
ID NLM: 0222643
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
revised:
17
07
2023
received:
19
05
2023
accepted:
23
07
2023
pubmed:
2
8
2023
medline:
2
8
2023
entrez:
2
8
2023
Statut:
ppublish
Résumé
We assessed the accuracy of preoperative gallium-68 DOTA-Tyr3-octreotate (DOTATATE) positron emission tomography (PET) imaging in estimating multifocality and nodal metastases of small bowel neuroendocrine tumors (sbNETs). A multicenter analysis was performed on patients with sbNETs who underwent preoperative DOTATATE PET imaging and surgical resection, with manual palpation of the entire length of the small bowel, between January 2016 and August 2022. Preoperative imaging reports and blinded secondary imaging reviews were compared to the final postoperative pathology reports. Descriptive statistics were applied. One-hundred and four patients met inclusion criteria. Pathology showed 53 (51%) patients had multifocal sbNETs and 96 (92%) had nodal metastases. The original preoperative DOTATATE PET imaging identified multifocal sbNET in 28 (27%) patients and lymph node (LN) metastases in 80 (77%) patients. Based on original radiology reports, sensitivity for multifocal sbNET identification was 45%, specificity was 92%, positive predictive value (PPV) was 86%, and negative predictive value (NPV) was 62%. For the identification of LN metastases, sensitivity was 82%, specificity was 88%, PPV was 99%, and NPV was 29%. Although DOTATATE PET imaging is specific and relatively accurate, sensitivity and NPV are insufficient to guide surgical planning. Preoperative use should not replace open palpation to identify additional synchronous lesions or to omit regional lymphadenectomy.
Sections du résumé
BACKGROUND AND OBJECTIVES
OBJECTIVE
We assessed the accuracy of preoperative gallium-68 DOTA-Tyr3-octreotate (DOTATATE) positron emission tomography (PET) imaging in estimating multifocality and nodal metastases of small bowel neuroendocrine tumors (sbNETs).
METHODS
METHODS
A multicenter analysis was performed on patients with sbNETs who underwent preoperative DOTATATE PET imaging and surgical resection, with manual palpation of the entire length of the small bowel, between January 2016 and August 2022. Preoperative imaging reports and blinded secondary imaging reviews were compared to the final postoperative pathology reports. Descriptive statistics were applied.
RESULTS
RESULTS
One-hundred and four patients met inclusion criteria. Pathology showed 53 (51%) patients had multifocal sbNETs and 96 (92%) had nodal metastases. The original preoperative DOTATATE PET imaging identified multifocal sbNET in 28 (27%) patients and lymph node (LN) metastases in 80 (77%) patients. Based on original radiology reports, sensitivity for multifocal sbNET identification was 45%, specificity was 92%, positive predictive value (PPV) was 86%, and negative predictive value (NPV) was 62%. For the identification of LN metastases, sensitivity was 82%, specificity was 88%, PPV was 99%, and NPV was 29%.
CONCLUSIONS
CONCLUSIONS
Although DOTATATE PET imaging is specific and relatively accurate, sensitivity and NPV are insufficient to guide surgical planning. Preoperative use should not replace open palpation to identify additional synchronous lesions or to omit regional lymphadenectomy.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1072-1079Informations de copyright
© 2023 Wiley Periodicals LLC.
Références
Clift AK, Kidd M, Bodei L, et al. Neuroendocrine neoplasms of the small bowel and pancreas. Neuroendocrinology. 2020;110(6):444-476.
Choi AB, Maxwell JE, Keck KJ, et al. Is multifocality an indicator of aggressive behavior in small bowel neuroendocrine tumors? Pancreas. 2017;46(9):1115-1120.
Gangi A, Siegel E, Barmparas G, et al. Multifocality in small bowel neuroendocrine tumors. J Gastrointest Surg. 2018;22(2):303-309.
Pasquer A, Poncet G. Small bowel neuroendocrine tumors surgery: technical point-with video. J Visceral Surg. 2017;154(1):61-62.
Pasquer A, Walter T, Milot L, Hervieu V, Poncet G. Principles of surgical management of small intestinal NET. Cancers. 2021;13(21):5473.
Young R, Rajkomar A, Smart P, Warrier S. Robotic-assisted complete mesocolic excision, central vascular ligation and para-aortic lymph node dissection in multifocal carcinoid: a case report and technical description. Int J Surg Case Rep. 2020;67:262-266.
Liu M, Wei L, Liu W, et al. Trends in incidence and survival in patients with gastrointestinal neuroendocrine tumors: a SEER database analysis, 1977-2016. Front Oncol. 2023;13:1079575.
Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncology. 2017;3(10):1335-1342.
White BE, Rous B, Chandrakumaran K, et al. Incidence and survival of neuroendocrine neoplasia in England 1995-2018: a retrospective, population-based study. The Lancet Regional Health - Europe. 2022;23:100510.
Scott AT, Howe JR. Management of small bowel neuroendocrine tumors. J Oncol Pract. 2018;14(8):471-482.
FDA. NETSPOT (kit for the preparation of gallium Ga 68 dotatate injection). 2016. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208547Orig1s000TOC.cfm
Rajamohan N, Khasawneh H, Singh A, et al. PET/CT and PET/MRI in neuroendocrine neoplasms. Abdominal Radiol. 2022;47(12):4058-4072.
Frilling A, Sotiropoulos GC, Radtke A, et al. The impact of 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors. Ann Surg. 2010;252(5):850-856.
Menon BK, Kalshetty A, Bhattacharjee A, Basu S. Standardized uptake values and ratios on 68Ga-DOTATATE PET-computed tomography for normal organs and malignant lesions and their correlation with Krenning score in patients with metastatic neuroendocrine tumors. Nucl Med Commun. 2020;41(10):1095-1099.
Howe JR, Cardona K, Fraker DL, et al. The surgical management of small bowel neuroendocrine tumors: consensus guidelines of the north American Neuroendocrine Tumor Society. Pancreas. 2017;46(6):715-731.
Navin PJ, Ehman EC, Liu JB, et al. Imaging of small-bowel neuroendocrine neoplasms: AJR expert panel narrative review. AJR Am J Roentgenol. 2023;221:1-3.
Froelich MF, Schnitzer ML, Holzgreve A, et al. Cost-effectiveness analysis of 68Ga DOTA-TATE PET/CT, 111In-pentetreotide SPECT/CT and CT for diagnostic workup of neuroendocrine tumors. Diagnostics. 2021;11(2):334.
Hope TA, Bergsland EK, Bozkurt MF, et al. Appropriate use criteria for somatostatin receptor PET imaging in neuroendocrine tumors. J Nucl Med. 2018;59(1):66-74.
Sanli Y, Garg I, Kandathil A, et al. Neuroendocrine tumor diagnosis and management: 68Ga-DOTATATE PET/CT. Am J Roentgenol. 2018;211(2):267-277.
Haug AR, Cindea-Drimus R, Auernhammer CJ, et al. The role of 68Ga-DOTATATE PET/CT in suspected neuroendocrine tumors. J Nucl Med. 2012;53(11):1686-1692.
Fendler WP, Barrio M, Spick C, et al. 68Ga-DOTATATE PET/CT interobserver agreement for neuroendocrine tumor assessments: results from a prospective study on 50 patients. J Nucl Med. 2017;58:307-311.
Jackson T, Darwish M, Cho E, Nagatomo K, Osman H, Jeyarajah DR. 68Ga-DOTATATE PET/CT compared to standard imaging in metastatic neuroendocrine tumors: a more sensitive test to detect liver metastasis? Abdominal Radiol. 2021;46(7):3179-3183.
Berzaczy D, Giraudo C, Haug AR, et al. Whole-body 68Ga-DOTANOC PET/MRI versus 68Ga-DOTANOC PET/CT in patients with neuroendocrine tumors: a prospective study in 28 patients. Clin Nucl Med. 2017;42(9):669-674.
Hallet J, Law C. Extent of lymph node dissection for small bowel neuroendocrine tumors. World J Surg. 2021;45(1):197-202.
Zaidi MY, Lopez-Aguiar AG, Dillhoff M, et al. Prognostic role of lymph node positivity and number of lymph nodes needed for accurately staging small-bowel neuroendocrine tumors. JAMA Surg. 2019;154(2):134-140.
Castillo C, Steffens T, Sim L, Caffery L. The effect of clinical information on radiology reporting: a systematic review. J Med Radiat Sci. 2021;68(1):60-74.
Obara P, Sevenster M, Travis A, Qian Y, Westin C, Chang PJ. Evaluating the referring physician's clinical history and indication as a means for communicating chronic conditions that are pertinent at the point of radiologic interpretation. J Digit Imaging. 2015;28(3):272-282.
Chingkoe CM, Brook A, Moser AJ, Mortele KJ. Subspecialized radiology review at multidisciplinary pancreas conference: impact on patient management. Abdom Radiol.2018;43(10):2783-2789.
Crawshaw BP, Chien H-L, Augestad KM, Delaney CP. Effect of laparoscopic surgery on health care utilization and costs in patients who undergo colectomy. JAMA Surg. 2015;150(5):410-415.
Yannos S, Athanasios P, Christos C, Evangelos F. History of biliary surgery. World J Surg. 2013;37(5):1006-1012.
Chang J, Rattner DW. History of minimally invasive surgical oncology. Surg Oncol Clin N Am. 2019;28(1):1-9.
Norlén O, Stålberg P, Öberg K, et al. Long-term results of surgery for small intestinal neuroendocrine tumors at a tertiary referral center. World J Surg. 2012;36(6):1419-1431.
Burke AP, Thomas RM, Elsayed AM, Sobin LH. Carcinoids of the jejunum and ileum: an immunohistochemical and clinicopathologic study of 167 cases. Cancer. 1997;79(6):1086-1093.
Keck KJ, Maxwell JE, Utria AF, et al. The distal predilection of small bowel neuroendocrine tumors. Ann Surg Oncol. 2018;25(11):3207-3213.
Figueiredo MN, Maggiori L, Gaujoux S, et al. Surgery for small-bowel neuroendocrine tumors: is there any benefit of the laparoscopic approach? Surg Endosc. 2014;28(5):1720-1726.
Massimino KP, Han E, Pommier SJ, Pommier RF. Laparoscopic surgical exploration is an effective strategy for locating occult primary neuroendocrine tumors. Am J Surg. 2012;203(5):628-631.
Reissman P, Shmailov S, Grozinsky-Glasberg S, Gross DJ. Laparoscopic resection of primary midgut carcinoid tumors. Surg Endosc. 2013;27(10):3678-3682.
Wang SC. Identification of unknown primary tumors in patients with neuroendocrine liver metastases. Arch Surg. 2010;145(3):276-280.
Molina MA, Goodwin WJ, Moffat FL, Serafini AN, Sfakianakis GN, Avisar E. Intra-operative use of PET probe for localization of FDG avid lesions. Cancer Imaging. 2009;9(1):59-62.
Rinehardt HN, Longo S, Gilbert R, et al. Handheld PET probe for pediatric cancer surgery. Cancers. 2022;14(9):2221.
Hall NC, Povoski SP, Murrey DA, Knopp MV, Martin EW Jr. Combined approach of perioperative 18F-FDG PET/CT imaging and intraoperative 18F-FDG handheld gamma probe detection for tumor localization and verification of complete tumor resection in breast cancer. World J Surg Oncol. 2007;5:143.
Gonzalez-Montoro A, Vera-Donoso CD, Konstantinou G, et al. Nuclear-medicine probes: where we are and where we are going. Med Phys. 2022;49(7):4372-4390.